

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Eye-tracking in adult depression: protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069256
Article Type:	Protocol
Date Submitted by the Author:	14-Oct-2022
Complete List of Authors:	Noyes, Blake; Queen's University, Centre for Neuroscience Studies Biorac, Aleks; Queen's University, Centre for Neuroscience Studies Vazquez, Gustavo; Queen's University, Centre for Neuroscience Studies; Queen's University, Department of Psychiatry Khalid-Khan, Sarosh; Queen's University, Centre for Neuroscience Studies; Queen's University, Department of Psychiatry Munoz, Douglas; Queen's University, Centre for Neuroscience Studies; Queen's University, Department of Biomedical and Molecular Sciences Booij, Linda; Concordia University, Psychology; CHU Sainte-Justine Centre de Recherche
Keywords:	Depression & mood disorders < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, Neurobiology < NATURAL SCIENCE DISCIPLINES

SCHOLARONE™
Manuscripts

1
2
3 Eye-tracking in adult depression: protocol for a systematic review and meta-analysis
4

5 Noyes, B.K.^a, Biorac, A.^a, Vazquez, G.H.^{a,b,e}, Khalid-Khan, S.^{a,b,e}, Munoz, D.P.^{*a,b,c,d}, &
6 Booiij, L.^{*a,d,f,g,h}.
7

8
9 *Co-Senior Authors
10

11 a Centre for Neuroscience Studies, Queen's University, Kingston, Canada

12 b Department of Medicine, Queen's University, Kingston, Canada

13 c Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Canada

14 d Department of Psychology, Queen's University, Kingston, Canada

15 e Department of Psychiatry, Queen's University, Kingston, Canada

16 f Department of Psychology, Concordia University, Montréal, Canada

17 g CHU Sainte-Justine Hospital Research Centre, University of Montréal, Montréal, Canada

18 h Department of Psychiatry, McGill University, Montréal, Canada
19
20

21 Blake K. Noyes: blake.noyes@queensu.ca

22 Aleks Biorac: aleks.biorac@queensu.ca

23 Gustavo H. Vazquez: g.vasquez@queensu.ca

24 Sarosh Khalid-Khan: sk83@queensu.ca

25 Douglas P. Munoz: doug.munoz@queensu.ca

26 Linda Booiij: linda.booiij@concordia.ca
27
28

29
30 Corresponding Author:

31 Linda Booiij

32 7141 Sherbrooke St. West

33 Montreal, QC

34 H4B 1R6
35
36

37 Contribution Statement: BKN drafted the initial manuscript. AB contributed additional text and
38 edits. DPM and LB provided edits. SKK, GHV, DPM, and LB supervised the work.
39

40 Indicate sources of financial or other support for the review: NA
41
42

43 Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol:
44 NA
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: In recent years, eye-tracking has been proposed as a promising tool to identify biomarkers for psychiatric disorders, including major depression. We will conduct an updated systematic review and meta-analysis on eye-tracking research in adults with major depressive disorder or other clinically diagnosed depressive disorders.

Methods and Analysis: This protocol follows all reporting items in the Preferred Reporting Items for Systematic review and Meta-Analysis – Protocol (PRISMA-P) extension. We will conduct a systematic search of PubMed, PsycInfo, Google Scholar, and EMBASE for sources published in the last 50 years (1972–2022). Abstract and full text review will be completed independently by two reviewers. Non-randomized studies utilizing eye-tracking tasks in individuals with a depressive disorder versus controls will be included. Eye-tracking tasks of interest include, but are not limited to, saccade, smooth pursuit, fixation, free-viewing, visual search, and attentional blink tasks. Results will be categorized by eye-tracking task. Risk of bias and confidence in cumulative evidence will be assessed using GRADE criteria.

Ethics and dissemination: Ethics approval is not required due to the nature of the proposed analysis. Results will be disseminated through a journal article, conference presentations, and/or dissertations.

Strengths and Limitations:

- This is the first meta-analysis of eye tracking in depression to include saccade tasks and smooth pursuit
- Inclusion of other depression diagnoses and subthreshold depression, in addition to MDD, will allow us to depict a more comprehensive picture of the population
- Sample size of some tasks, such as the attentional blink task, may be small

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Due to the large date range, comparability of results may be challenging due to different eye tracking technologies

For peer review only

BACKGROUND

Major depressive disorder (MDD) is the leading cause of disability worldwide (World Health Organization, 2017). According to the most recent edition of the Diagnostic Statistical Manual of Mental Disorders (DSM-5; American Psychiatric Association, 2013), MDD is characterized by having low mood and/or low interest/pleasure all day nearly every day for at least two weeks, as well as having a total of five out of nine listed symptoms (American Psychiatric Association, 2013). The presence of MDD has been found to significantly impact life satisfaction and functioning, with associations with marital dissatisfaction, lower income, more missed work, and cognitive impairments (Kessler, 2012), as well as increased risk for comorbid psychiatric disorders (Hasin et al., 2018). Recurrent depression, in comparison to single major depression episodes, are associated with impaired psychosocial functioning in adulthood, including lower positive and higher negative emotionality, more antisocial behaviour, increased use of mental health services, and increased suicidal ideation (Wilson et al., 2015).

Despite continued efforts to identify biomarkers (e.g., candidate genes, blood-based markers, structural or functional neuroimaging markers, etc.) for depression, research has been unsuccessful at identifying a reliable biomarker to integrate into clinical practice (Kraus et al., 2019). Eye-movements, such as saccades, pupil dilation/constriction, and blinks, have been previously investigated and linked to specific brain structures and networks, and thus may be used to identify impaired functioning in the brain (Habibi et al., 2022; Coe & Munoz, 2017; Wang & Munoz, 2015; Leigh & Zee, 2015). Thus, due to the known relation between eye-tracking tasks and brain areas required for their execution, eye-tracking has emerged as a useful tool for identifying potential biomarkers for neurological and psychiatric disorders. Unlike other biomarker identification methods, such as neuroimaging, eye-tracking is comparatively cost-

1
2
3 effective and non-invasive, simply requiring the participant to sit in front of a computer screen
4
5 with their head on a chin rest while an infrared camera tracks their eyes. Thus, eye-tracking is a
6
7 promising method to identify neural markers for depression, which may lead to early
8
9 identification in at-risk individuals.
10

11
12 A variety of task paradigms has been utilized in eye-tracking research to probe specific
13
14 brain functions. Commonly used are saccade tasks, which require participants to make saccades
15
16 to different areas on a screen. Variations of saccade tasks include the pro-saccade (requiring
17
18 participants to look towards a visible target), anti-saccade (requiring participants to look away
19
20 from a visible target), predictive/anticipatory saccade (requiring participants to make a saccade
21
22 from a visible target), predictive/anticipatory saccade (requiring participants to make a saccade
23
24 to a location before a target appears), and memory-guided saccade (requiring participants to
25
26 make a saccade to the remembered position of a target after it has disappeared). Fixation tasks
27
28 (requiring participants to keep their gaze on one target) and smooth pursuit tasks (requiring
29
30 participants to keep their eyes on a moving target) have also been employed. Finally,
31
32 unstructured free-viewing tasks (allowing participants to look wherever they please) of varying
33
34 stimuli and visual search tasks have become increasingly popular in eye-tracking research.
35
36 Multiple types of outcomes can be examined from these tasks, including saccade metrics (e.g.,
37
38 saccadic reaction time), pupil metrics (e.g., baseline pupil size), blink metrics (e.g., blink rate),
39
40 and performance metrics (e.g., error rate).
41
42
43

44
45 Eye-tracking research in clinical populations, including in individuals with MDD, has
46
47 grown substantially in the last decade (Figure 1). To the authors' knowledge, only three reviews
48
49 exist on eye-tracking in depression. Two of these are systematic reviews and meta-analyses on
50
51 free-viewing tasks in depression – Suslow and colleagues (2020), which included sixteen studies,
52
53 and Armstrong and Olatunji (2012), which included nine studies. The third review is a
54
55
56
57
58
59
60

1
2
3 systematic review on various eye-tracking tasks in depression, which included 43 studies, and
4
5 had a broader scope (Carvalho et al., 2015).
6
7

8 In their review, Carvalho and colleagues (2015) identified several differences in eye-
9
10 movement behaviour between individuals with MDD and controls. In comparison to controls,
11
12 those with MDD had increased reaction time during the pro and anti-saccade tasks, decreased
13
14 accuracy in the pro-saccade task, increased error rate during the anti-saccade task. They also had
15
16 decreased accuracy during the predictive saccade task, decreased reaction time during the
17
18 memory-guided saccade task, and lower pursuit gain and greater catch-up-saccade rates in
19
20 smooth pursuit tasks (Carvalho et al., 2015). For free-viewing and visual search tasks, those with
21
22 MDD, as well as those with bipolar disorder in depressive phase, exhibited increased attention to
23
24 negative (anger, dysphoric, sadness, anxiety-related, depression-related) stimuli and decreased
25
26 attention to positive stimuli (Carvalho et al., 2015). Finally, the authors reviewed the effects of
27
28 medication (such as benzodiazepines, anti-depressants, and anti-psychotic drugs) on oculomotor
29
30 behaviour, and noted the need for controlling for medication when examining eye-movements in
31
32 depression and bipolar disorder (Carvalho et al., 2015).
33
34
35
36
37

38 Armstrong & Olatunji (2012) and Suslow and colleagues (2020) also found differences
39
40 between eye-tracking of attention in those with MDD compared to healthy individuals. Suslow
41
42 and colleagues' recent meta-analysis found no group differences in initial orientation of attention
43
44 but found moderate to large effect sizes when looking at maintenance of gaze to various types of
45
46 stimuli during free viewing of images. Across studies, individuals with depressed individuals
47
48 looked less at positive images (Hedge's $g = -.51$) and happy faces ($g = -.54$) and longer for
49
50 dysphoric images ($g = .66$) and sad faces ($g = .58$) than healthy individuals (Suslow et al., 2020).
51
52
53
54 The previous meta-analysis by Armstrong and Olatunji (2012) reported that, for orientation,
55
56
57
58
59
60

1
2
3 there was no difference between depressed individuals and healthy participants for threatening (g
4 = -.01) or dysphoric images (g = .18). However, they found individuals with depression oriented
5
6 less towards positive stimuli (g = -.24; Armstrong & Olatunji, 2012). For maintenance of gaze,
7
8 there was again no difference for threatening stimuli (g = .08), but an increase in gaze
9
10 maintenance for depressed individuals for dysphoric stimuli (g = .46) and a decrease in positive
11
12 stimuli (g = -.80) compared to healthy participants (Armstrong & Olatunji, 2012).
13
14
15

16
17 The current systematic review and meta-analysis will discuss and quantify results from
18
19 eye-tracking literature with a focus on adults with MDD in comparison to healthy controls, as
20
21 well as other clinically rated depressive disorders (i.e., persistent depressive disorder/dysthymia,
22
23 dysphoria, bipolar disorder in depressive phase, disruptive mood dysregulation disorder,
24
25 premenstrual dysphoric disorder, seasonal affective disorder, minor depression, subthreshold
26
27 depression). Although excluded in prior literature, inclusion of conditions such as subthreshold
28
29 depression in biomarker research is warranted due to the clinical similarity to MDD (Noyes et
30
31 al., 2022). Similar to Carvalho et al. (2015), we will include data from saccade, smooth pursuit,
32
33 fixation, free-viewing, and visual search tasks. Additionally, we will cover tasks not previously
34
35 examined by other reviews (e.g., attentional blink task). Eye-tracking outcomes include, but are
36
37 not limited to, saccades (number, rate, types), saccadic amplitude and velocity, reaction time,
38
39 error rate and accuracy, eye position, fixation count and fixation duration, blinks, and pupil
40
41 dilation/constriction. As the last systematic review on many of these eye-tracking tasks was
42
43 published in 2015, an update on adult eye-tracking in depression is necessary given the growth in
44
45 literature over the past seven years. To the authors' knowledge, this will also be the first meta-
46
47 analysis to include saccade, smooth pursuit, and fixation tasks, as well as blink and pupil
48
49 measures, which is important as these tasks implicate different neural networks. As a result, this
50
51
52
53
54
55
56
57
58
59
60

1
2
3 paper may aid in identifying potential eye movement biomarkers for depression and allow for
4
5 earlier identification of illness.
6

7 8 **METHOD**

9
10 This protocol covers all items outlined under the Preferred Reporting Items for Systematic
11
12 Reviews and Meta-Analysis Protocols (PRISMA-P; Moher et al., 2015).
13

14 15 **ELIGIBILITY CRITERIA:**

16
17 **Types of studies:** Experimental studies performed in a controlled laboratory environment will be
18
19 included. Any experimental sessions, including longitudinal work, that include eye tracking tasks
20
21 and eye movement outcomes will be included. Case reports and case series will be excluded.
22

23
24 **Types of participants:** We will review studies involving study participants with a mean age
25
26 between 18–60 years, and depression symptomatology must be clinically rated or diagnosed (not
27
28 reliant on self-report measures only). Individuals with a primary diagnosis of major depressive
29
30 disorder, persistent depressive disorder/dysthymia, dysphoria, disruptive mood dysregulation
31
32 disorder, seasonal affective disorder, minor/subclinical/subthreshold depression, according to
33
34 established criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM; any
35
36 version) or of the International Classification of Diseases (ICD; any version). Studies involving
37
38 individuals with diagnosed bipolar disorder in depressive phase will be included, and studies
39
40 involving mixed samples of bipolar phases will be included if depressive phase data can be
41
42 isolated. Studies will not be included if they utilize experimental mood induction procedures or if
43
44 participants have a psychotic disorder.
45
46

47
48
49 **Type of control:** Studies must also have a healthy (no psychiatric history) control participant
50
51 group with a mean age between 18-60 years.
52
53
54
55
56
57
58
59
60

Types of interventions: The tasks/measures reviewed by Carvalho et al. (2015) will be included: pro-saccades, anti-saccades, predictive saccades, memory-guided saccades, smooth pursuit eye movements, fixation tasks, and free-viewing/search tasks, as well as the attentional blink task (see Table 1 for definitions). Additional tasks that are found not to fit in these categories will be included if sufficient data exist. Tasks must have performance (e.g., reaction time, error rate, accuracy) saccade, pupil, or blink data to be included in analyses.

Task	Definition
Pro-Saccade, Reflexive Saccades, Visually Guided Saccades, Refixation Saccades	Requires participants to look towards a visible stimulus
Anti-Saccade	Requires participants to look away from a visible stimulus
Memory-Guided Saccade	Requires participants to look to a location where a target was previously presented
Predictive Saccade, Oddball Task, Self-Paced Saccade	Requires participants to look to anticipated target location after receiving some warning or cue
Fixation, No Saccade	Requires participants to maintain gaze on a target in the centre of the screen
Free-Viewing	Allows participant to look freely at images or videos that appear
Visual Search	Requires participant to search for stimuli in a scene, or to compare multiple scenes
Smooth Pursuit	Requires participants to track a moving target
Attentional Blink	Requires participants to report two targets that appear one after another

Table 1. Definition of various eye-movement tasks (Leigh & Zee, 2015; Carvalho et al., 2015; Shapiro et al., 1997).

Type of outcomes: eye movement outcomes will include, but are not limited to,

Performance metrics: accuracy, correction factors, error rates, reaction time, response search score

Saccade/fixation metrics: saccade type (back-up, catch-up, corrective, intrusive micro, macro), saccade amplitude, saccade count/rate, saccadic duration, saccadic peak velocity, saccade position error, intersaccadic interval, direction of initial eye movement, eye

scanning length (mean, total), pursuit (gain, latency), first/initial fixation (location, duration, latency), fixation bias, fixation duration, fixation frequencies, fixation number, percentage of time fixating, scan path length, maintenance of gaze, mean gaze duration, final eye position, root mean square, root mean square error, square wave jerk, time-weight average gain, target waveform

Pupil metrics: baseline pupil size, pupil constriction, pupil dilation

Blink metrics: blink duration, blink rate, inter blink interval

The following outcomes will be prioritized due to their frequency in the literature: task accuracy, error rate, fixation duration/maintenance of gaze, and reaction time. Additionally, we will prioritize pupil and blink outcomes as those have emerged as promising biomarkers in our laboratory.

PICOs Criteria	Determinants
Patient	Individuals with MDD, persistent depressive disorder/dysthymia, dysphoria, disruptive mood dysregulation disorder, seasonal affective disorder, minor/subclinical/subthreshold depression, or bipolar disorder in depressive phase. Mean age of study sample must be between 18-60 years.
Intervention	Any eye tracking tasks (saccade tasks, smooth pursuit tasks, fixation tasks, free-viewing tasks, visual search tasks, attentional blink task)
Comparison	Healthy individuals, mean of study sample between 18-60 years.
Outcome	Task performance and any eye movement outcome (performance, saccade/fixation, pupil, and blink metrics; see above)
Study design	Experimental non-randomized studies

Table 2. PICOs criteria and determinants.

INFORMATION SOURCES:

Journal articles or conference papers in English, French, German, Dutch, and Portuguese published online from the years 1972–2022 will be reviewed. Included studies were not limited by geographic location. The electronic databases searched will include PubMed, PsycInfo, EMBASE and Google Scholar. Reference lists of highly relevant articles will also be examined.

1
2
3 If full text of papers cannot be accessed, attempts to contact authors will be made. Conference
4 posters, abstracts, and student papers will not be included.
5
6

7 **SEARCH STRATEGY:**

8
9
10 The following is the utilized search strategy for PubMed. All searches will be completed for
11 Title/Abstract, and filtered for journal articles, full text, and publication years. The same search
12 strategy will be repeated across databases with minor changes to adjust for database search tools.
13
14
15

16 **Search terms:**

- 17 1. depress OR mood AND eye tracking OR saccad* OR pupil OR blink OR smooth
18 pursuit
- 19 2. dysthymi* AND eye tracking OR saccad* OR pupil OR blink OR smooth pursuit
- 20 3. dysphori* AND eye tracking OR saccad* OR pupil OR blink OR smooth pursuit
- 21 4. seasonal affective disorder AND eye tracking OR saccad* OR pupil OR blink OR
22 smooth pursuit
- 23 5. bipolar AND eye tracking OR saccad* OR pupil OR blink OR smooth pursuit
24
25
26

27 Search strategies for other databases (Appendix 1) were determined via consensus among the
28 authors.
29
30

31 **DATA RECORDS AND MANAGEMENT:**

32
33
34 Excel spreadsheets will be used to manage records at abstract level, full text review, and data
35 extraction. BKN will perform the initial search and copy relevant information (authors,
36 publication year, title, link to access) from all search hits into an excel spreadsheet and will send
37 the completed spreadsheet to AB. BKN and AB will extract abstracts, screen abstracts for
38 eligibility, and conduct the full-text review independently. Kappa will be used to quantify the
39 level of inter-rater agreement. In the event of discrepancies at abstract or full text review, a third
40 reviewer will make the final decision on inclusion (DPM for discrepancies involving eye
41 tracking methodology, LB for discrepancies involving participants and all other issues).
42
43
44
45
46
47
48
49
50
51

52 Data tables will be independently piloted with 10 papers to ensure all necessary information is
53 being extracted. The following data items will be extracted for saccade and smooth pursuit tasks:
54
55
56
57
58
59
60

1
2
3 N (by diagnosis)
4 Mean age and SD
5 Sex/gender
6 Ethnicity
7 Comorbidities
8 Diagnostic method
9 Interventions/treatment
10 Eye-tracking tasks
11 Eye-movement outcomes
12 Results
13
14
15

16 The same data items will be extracted for free-viewing and visual search tasks, with the addition
17 of stimuli (type and emotional valence).
18
19

20 **EFFECT MEASURES:**

21 Eye tracking outcome measures between patient groups and healthy controls will primarily be
22 reported as mean differences and their respective standard deviation. We will use mean
23 differences for measures (+/-SD) such as of the number of saccade rate and task error rates,
24 saccade amplitude and velocity, reaction time, fixation count and duration, number of blinks, and
25 pupillometry data.
26
27
28
29
30
31
32
33

34 **RISK OF BIAS:**

35 Bias will be assessed by two independent researchers (BKN and AB) and discrepancies will be
36 addressed by LB and DPM. We will investigate in greater detail multiple publications coming
37 out from the same research group and we will assess sample size and sample demographics to
38 check for duplication. In case of overlapping samples/results, the first published reference will be
39 included in the analyses, unless methodology is not sufficiently detailed to be included.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Publication bias will be assessed using a funnel plot method (Duval & Tweedie, 2000).

61 **DATA SYNTHESIS:**

62 The PRISMA flowchart will be presented to explain how and the number of articles that were
63 retrieved/selected. Results from included individual studies will be categorized by eye-tracking
64
65
66
67
68
69
70

1
2
3 task and expressed both narratively and in data tables. Means, standard deviation, effect sizes,
4 and statistical significance will be reported. It is anticipated that effect sizes will be expressed as
5 Cohen's D. A meta-analysis will be performed if data from three or more studies exist for the
6 same eye-tracking task. It is anticipated that JASP will be used to do the meta-analyses, though
7 other software will be considered at the time of analyses. To assess whether the results are
8 homogenous, the Q statistic will be calculated (Cooper, 2017).
9
10
11
12
13
14
15

16 **CONFIDENCE IN CUMULATIVE EVIDENCE:**

17
18 BKN and AB will independently assess the strength and quality of evidence using Grading of
19 Recommendations, Assessment, Development and Evaluation (GRADE; Guyatt et al., 2008)
20 approach criteria, a tool for meta-analyses that assesses study limitations, inconsistency of
21 results, indirectness of evidence, imprecision, and reporting bias. Strength of evidence will be
22 rated as very low, low, moderate, or high. In the event of discrepancies on GRADE rating, LB
23 and DPM will make the final decision. A quality assessment table will be presented to display
24 which studies were included and which were excluded.
25
26
27
28
29
30
31
32
33
34

35 **ETHICS AND DISSEMINATION:**

36
37 Not applicable - ethics approval is not required due to the nature of this work. Results will be
38 analyzed and disseminated according to systematic review and meta-analyses protocol and
39 submitted to an academic journal for publication.
40
41
42
43

44 **PATIENT AND PUBLIC INVOLVEMENT:**

45
46 Due to the nature of this study, there will be no patient or public involvement.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

There is a growing need to identify reliable biomarkers of psychiatric disease, specifically as they relate to depressive disorders, to improve early diagnosis and treatment.

Research into psychiatric biomarkers using eye tracking has grown steadily in recent years, as this method offers the ability to use a variety of different task paradigms and is relatively cost-effective. Given the surge in eye tracking-related research for depression biomarkers, it is paramount to summarize these findings to effectively identify potential behavioural biomarkers.

This meta-analysis aims to update the knowledge that has been reported previously by past meta-analyses on attentional tasks in depression (Suslow et al., 2020; Armstrong & Olatunji, 2012), provide the first meta-analyses of saccade, fixation, and smooth pursuit tasks in depression, as well as extend the body of knowledge by including task paradigms and outcomes not previously covered (e.g., attentional blinks). By using methodology as outlined by PRISMA guidelines, this meta-analysis aims to provide a comprehensive overview of current study findings which may help inform future clinical practice in the diagnosis and treatment of depression (and other related disorders). However, while this meta-analysis will attempt to extend the body of knowledge by considering studies using tasks not previously covered by other reviews (e.g., attentional blink task) and those including various depressive disorder populations (i.e., not simply individuals diagnosed with MDD), this may be limited by the number of published studies and their quality.

References (APA)

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). <https://doi.org/10.1176/appi.books.9780890425596>

Armstrong, T., & Olatunji, B. O. (2012). Eye tracking of attention in the affective disorders: a meta-analytic review and synthesis. *Clinical psychology review*, 32(8), 704–723.

<https://doi.org/10.1016/j.cpr.2012.09.004>

Carvalho, N., Laurent, E., Noiret, N., Chopard, G., Haffen, E., Bennabi, D., & Vandel, P. (2015). Eye Movement in Unipolar and Bipolar Depression: A Systematic Review of the Literature.

Frontiers in psychology, 6, 1809. <https://doi.org/10.3389/fpsyg.2015.01809>

Cooper, H. (2017). Research synthesis and meta-analysis: A step-by-step approach (Vol. 2, 5th ed.). Thousand Oaks, CA: Sage Publications, Inc.

Coe, B. C., & Munoz, D. P. (2017). Mechanisms of saccade suppression revealed in the anti-saccade task. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences*, 372(1718), 20160192. <https://doi.org/10.1098/rstb.2016.0192>

Duval, S., & Tweedie, R. (2000). Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*, 56(2), 455–463. <https://doi.org.proxy.queensu.ca/10.1111/j.0006-341x.2000.00455.x>

Farrah, K., Young, K., Tunis, M.C., & Zhao, L. (2019). Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols. *Syst Rev* 8, 280.

<https://doi.org/10.1186/s13643-019-1172-8>

Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P.,

Schünemann, H. J., & GRADE Working Group (2008). GRADE: an emerging consensus on

1
2
3 rating quality of evidence and strength of recommendations. *BMJ (Clinical research ed.)*,
4 336(7650), 924–926. <https://doi.org/10.1136/bmj.39489.470347.AD>

7 Habibi, M., Oertel, W. H., White, B. J., Brien, D. C., Coe, B. C., Riek, H. C., Perkins, J., Yep,
8 R., Itti, L., Timmermann, L., Best, C., Sittig, E., Janzen, A., & Munoz, D. P. (2022). Eye
9 tracking identifies biomarkers in α -synucleinopathies versus progressive supranuclear palsy.

11 *Journal of neurology*, 269(9), 4920–4938. <https://doi.org/10.1007/s00415-022-11136-5>

13
14
15
16
17 Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F.
18 (2018). Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the
19 United States. *JAMA psychiatry*, 75(4), 336–346.

21
22
23
24 <https://doi.org/10.1001/jamapsychiatry.2017.4602>

25
26
27
28
29 Kessler R. C. (2012). The costs of depression. *The Psychiatric clinics of North America*, 35(1),
1–14. <https://doi.org/10.1016/j.psc.2011.11.005>

30
31
32
33
34 Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., Jr, & Kasper, S. (2019). Prognosis and
improved outcomes in major depression: a review. *Translational psychiatry*, 9(1), 127.

35
36
37 <https://doi.org/10.1038/s41398-019-0460-3>

38
39
40
41 Leigh, R.J., & Zee D.S. (Eds.). (2015). *The Neurology of Eye Movements: Fifth Edition*. Oxford
<https://doi.org/10.1093/med/9780199969289.001.0001>

42
43
44 Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P.,

45
46
47
48 Stewart, L. A., & PRISMA-P Group (2015). Preferred reporting items for systematic review and
meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews*, 4(1), 1.

49
50
51
52
53
54
55
56
57
58
59
60 <https://doi.org/10.1186/2046-4053-4-1>

1
2
3 Noyes, B. K., Munoz, D. P., Khalid-Khan, S., Brietzke, E., & Booij, L. (2022). Is subthreshold
4 depression in adolescence clinically relevant?. *Journal of affective disorders*, 309, 123–130.

5
6
7 <https://doi.org/10.1016/j.jad.2022.04.067>

8
9
10 Shapiro, K. L., Raymond, J. E., & Arnell, K. M. (1997). The attentional blink. *Trends in*
11
12 *cognitive sciences*, 1(8), 291–296. [https://doi.org/10.1016/S1364-6613\(97\)01094-2](https://doi.org/10.1016/S1364-6613(97)01094-2)

13
14 Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M.,
15
16 Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., Carpenter, J. R., Chan, A. W., Churchill,
17
18 R., Deeks, J. J., Hróbjartsson, A., Kirkham, J., Jüni, P., Loke, Y. K., Pigott, T. D., Ramsay, C.
19
20 R., ... Higgins, J. P. (2016). ROBINS-I: a tool for assessing risk of bias in non-randomised
21
22 studies of interventions. *BMJ (Clinical research ed.)*, 355, i4919. [https://doi-](https://doi-
23
24
25
26
27 org.proxy.queensu.ca/10.1136/bmj.i4919)

28
29 Suslow, T., Hußlack, A., Kersting, A., & Bodenschatz, C. M. (2020). Attentional biases to
30
31 emotional information in clinical depression: A systematic and meta-analytic review of eye
32
33 tracking findings. *Journal of affective disorders*, 274, 632–642.

34
35
36 <https://doi.org/10.1016/j.jad.2020.05.140>

37
38 Wang, C. A., & Munoz, D. P. (2015). A circuit for pupil orienting responses: implications for
39
40 cognitive modulation of pupil size. *Current opinion in neurobiology*, 33, 134–140.

41
42
43 <https://doi.org/10.1016/j.conb.2015.03.018>

44
45 Wilson, S., Hicks, B. M., Foster, K. T., McGue, M., & Iacono, W. G. (2015). Age of onset and
46
47 course of major depressive disorder: associations with psychosocial functioning outcomes in
48
49 adulthood. *Psychological medicine*, 45(3), 505–514.


50
51
52 <https://doi.org/10.1017/S0033291714001640>

1
2
3 License Statement:
4

5 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
6 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive
7 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has
8 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US
9 Federal Government officers or employees acting as part of their official duties; on a worldwide,
10 perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and
11 where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the
12 Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in
13 our [licence](#).
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 The Submitting Author accepts and understands that any supply made under these terms is made
29 by BMJ to the Submitting Author unless you are acting as an employee on behalf of your
30 employer or a postgraduate student of an affiliated institution which is paying any applicable
31 article publishing charge (“APC”) for Open Access articles. Where the Submitting Author
32 wishes to make the Work available on an Open Access basis (and intends to pay the relevant
33 APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence
34 – details of these licences and which [Creative Commons](#) licence will apply to this Work are set
35 out in our licence referred to above.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



ew only

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	5a	Indicate sources of financial or other support for the review
Sponsor	5b	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Study records:		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review

1			
2			
3	Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
4			
5	Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
6			
7	Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
8			
9	Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
10			
11	Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
12			
13	Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised
14		15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)
15		15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)
16		15d	If quantitative synthesis is not appropriate, describe the type of summary planned
17			
18	Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
19			
20	Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)
21			

22 *** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on**
 23 **the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is**
 24 **distributed under a Creative Commons Attribution Licence 4.0.**
 25

26
 27 *From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and*
 28 *meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46

BMJ Open

Eye-tracking in adult depression: protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069256.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Mar-2023
Complete List of Authors:	Noyes, Blake; Queen's University, Centre for Neuroscience Studies Biorac, Aleks; Queen's University, Centre for Neuroscience Studies Vazquez, Gustavo; Queen's University, Department of Psychiatry; Queen's University, Centre for Neuroscience Studies Khalid-Khan, Sarosh; Queen's University, Centre for Neuroscience Studies; Queen's University, Department of Psychiatry Munoz, Douglas; Queen's University, Centre for Neuroscience Studies; Queen's University, Department of Biomedical and Molecular Sciences Booij, Linda; McGill University, Department of Psychiatry; Douglas Mental Health University Institute, Research Centre
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Research methods
Keywords:	Depression & mood disorders < PSYCHIATRY, Adult psychiatry < PSYCHIATRY, Neurobiology < NATURAL SCIENCE DISCIPLINES

SCHOLARONE™
Manuscripts

1
2
3 Eye-tracking in adult depression: protocol for a systematic review and meta-analysis
4

5 Noyes, B.K.^a, Biorac, A.^a, Vazquez, G.H.^{a,b,e}, Khalid-Khan, S.^{a,b,e}, Munoz, D.P.^{*a,b,c,d}, &
6 Booiij, L.^{*d,f,g}.
7

8
9 *Co-Senior Authors
10

11 a Centre for Neuroscience Studies, Queen's University, Kingston, Canada

12 b Department of Medicine, Queen's University, Kingston, Canada

13 c Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Canada

14 d Department of Psychology, Queen's University, Kingston, Canada

15 e Department of Psychiatry, Queen's University, Kingston, Canada

16 f Research Centre, Douglas Mental Health University Institute, Montréal, Canada

17 g Department of Psychiatry, McGill University, Montréal, Canada
18
19

20 Blake K. Noyes: blake.noyes@queensu.ca

21 Aleks Biorac: aleks.biorac@queensu.ca

22 Gustavo H. Vazquez: g.vazquez@queensu.ca

23 Sarosh Khalid-Khan: sk83@queensu.ca

24 Douglas P. Munoz: doug.munoz@queensu.ca

25 Linda Booiij: linda.booiij@mcgill.ca
26
27

28
29 Corresponding Author:

30 Linda Booiij

31 McGill University and Douglas Mental Health University Institute

32 6605, boul. LaSalle,

33 Montreal, QC, H4H 1R3
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: In recent years, eye-tracking has been proposed as a promising tool to identify potential biomarkers for mental disorders, including major depression. We will conduct an updated systematic review and meta-analysis on eye-tracking research in adults with major depressive disorder or other clinically diagnosed depressive disorders.

Methods and Analysis: This protocol follows all reporting items in the Preferred Reporting Items for Systematic review and Meta-Analysis – Protocol (PRISMA-P) extension. We will conduct a systematic search of PubMed, PsycInfo, Google Scholar, and EMBASE for sources published up until March 2023. Abstract and full text review will be completed independently by two reviewers. Non-randomized studies utilizing eye movement tasks in individuals with a depressive disorder versus controls will be included. Eye movement tasks of interest include, but are not limited to, saccade, smooth pursuit, fixation, free-viewing, attentional disengagement, visual search, and attentional blink tasks. Results will be categorized by eye movement task. Risk of bias will be assessed using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies and confidence in cumulative evidence will be assessed using GRADE criteria.

Ethics and dissemination: Ethics approval is not required due to the nature of the proposed analysis. Results will be disseminated through a journal article, conference presentations, and/or dissertations.

Strengths and Limitations:

- This is the first meta-analysis of eye-tracking in depression to include saccade tasks and smooth pursuit
- Inclusion of other depression diagnoses and subthreshold depression, in addition to MDD, will allow us to depict a more comprehensive picture of the population
- Sample size of some tasks, such as the attentional blink task, may be small
- Due to the large date range, comparability of results may be challenging due to different eye-tracking technologies and analyses employed

RATIONALE:

Major depressive disorder (MDD) is the leading cause of disability worldwide.[1] According to the most recent edition of the Diagnostic Statistical Manual of Mental Disorders (DSM-5), MDD is characterized by having low mood and/or low interest/pleasure all day nearly every day for at least two weeks, as well as having a total of five out of nine listed symptoms.[2] Similarly, in the latest edition of the International Classification of Diseases (ICD-11), a depressive episode requires a total of five out of ten listed symptoms to be present, with one being either low mood or low interest/pleasure.[3] The presence of MDD has been found to significantly impact life satisfaction and functioning, with associations to marital dissatisfaction, lower income, more missed work, and cognitive impairment,[4] as well as increased risk for comorbid mental disorders.[5] In comparison to single major depressive episodes, recurrent depression is associated with impaired psychosocial functioning in adulthood, including lower positive and higher negative emotionality, more antisocial behaviour, increased use of mental health services, and increased suicidal ideation.[6]

Despite continued efforts to identify biomarkers (e.g., candidate genes, blood-based markers, structural or functional neuroimaging markers, etc.) for depression, research has been unsuccessful at identifying a reliable biomarker to integrate into clinical practice.[7] However, the growing field of eye-tracking in mental disorders may be able to address this issue. Unlike other methods, such as neuroimaging, eye-tracking is comparatively cost-effective and non-invasive, making it an accessible and attractive option for researchers, study participants, and patients. Eye movement behaviour, such as saccades or pupil responses, have been previously investigated and linked to specific brain structures and networks, and therefore may be used to identify impaired functioning in specific brain areas and networks.[8-12] For example, eye

1
2
3 movement tasks can be designed to target areas responsible motor control, cognitive processes
4 (e.g., inhibitory control), and emotion.[13-14] In mental disorders such as depression, eye-
5 tracking has emerged as a useful tool to understand alterations in cognitive and emotional
6 processes.[15] Thus, eye-tracking is a promising method to improve psychological models of
7 disorders, study progression of illness, and identify neural markers, which may lead to improved
8 interventions and early identification in at-risk individuals.
9

10
11
12
13
14
15
16
17 A variety of tasks or paradigms have been utilized in eye-tracking research to probe
18 specific brain functions. Commonly used are saccade tasks, which require participants to make
19 eye movements to different areas on a computer monitor. Variations of saccade tasks include the
20 pro-saccade (requiring participants to look towards a visible target), anti-saccade (requiring
21 participants to look away from a visible target), predictive/anticipatory saccade (requiring
22 participants to make a saccade to a location before a target appears), and memory-guided saccade
23 (requiring participants to make a saccade to the remembered position of a target after it has
24 disappeared). Fixation tasks (requiring participants to keep their gaze on one target) and smooth
25 pursuit tasks (requiring participants to keep their eyes on a moving target) have also been
26 employed. Finally, unstructured free-viewing tasks (allowing participants to look wherever they
27 please) of varying stimuli, attentional disengagement tasks, and visual search tasks have become
28 increasingly popular in eye-tracking research. Multiple types of outcomes can be examined from
29 these tasks, including saccade metrics (e.g., saccadic reaction time), pupil metrics (e.g., baseline
30 pupil size), blink metrics (e.g., blink rate), and performance metrics (e.g., error rate).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Eye-tracking research in clinical populations, including in individuals with MDD, has
50 grown substantially in the last decade (Figure 1). To the authors' knowledge, only three reviews
51 exist on eye-tracking in depression. Two of these are systematic reviews and meta-analyses on
52
53
54
55
56
57
58
59
60

1
2
3 free-viewing tasks in depression – Suslow and colleagues[14], which included sixteen studies,
4 and Armstrong and Olatunji[16], which included nine studies. The third review is a systematic
5
6 review on various eye movement tasks in depression, which included 43 studies, and had a
7
8 broader scope.[15]
9
10

11
12 In their review, Carvalho and colleagues[15] identified several differences in eye-
13
14 movement behaviour between individuals with MDD and controls. In comparison to controls,
15
16 those with MDD had increased reaction time during the pro and anti-saccade tasks, decreased
17
18 accuracy in the pro-saccade task, and increased error rate during the anti-saccade task. They also
19
20 had decreased accuracy during the predictive saccade task, decreased reaction time during the
21
22 memory-guided saccade task, and lower pursuit gain and greater catch-up-saccade rates in
23
24 smooth pursuit tasks.[15] For free-viewing and visual search tasks, those with MDD, as well as
25
26 those with bipolar disorder in depressive phase, exhibited increased attention to negative (anger,
27
28 dysphoric, sadness, anxiety-related, depression-related) stimuli and decreased attention to
29
30 positive stimuli.[15] Finally, the authors reviewed the effects of medication (such as
31
32 benzodiazepines, anti-depressants, and anti-psychotic drugs) on oculomotor behaviour, and noted
33
34 the need to control for medication when examining eye-movements in depression and bipolar
35
36 disorder.[15]
37
38
39
40
41

42 In their meta-analyses, Armstrong and Olatunji[16] and Suslow and colleagues[14]
43
44 quantified differences between eye-tracking of attention in those with MDD compared to healthy
45
46 individuals. Suslow and colleagues found no group differences in initial orientation of attention
47
48 but found moderate to large effect sizes when looking at maintenance of gaze to various types of
49
50 stimuli during free viewing of images. Across studies, individuals with depression looked less at
51
52 positive images (Hedge's $g = -.51$) and happy faces ($g = -.54$) and longer for dysphoric images
53
54
55
56
57
58
59
60

1
2
3 (g = .66) and sad faces (g = .58) than healthy individuals.[14] The previous meta-analysis by
4
5 Armstrong and Olatunji[16] reported that, for orientation, there was no difference between
6
7 depressed individuals and healthy participants for threatening (g = -.01) or dysphoric images
8
9 (g = .18). However, they found individuals with depression oriented less towards positive stimuli
10
11 (g = -.24).[16] For maintenance of gaze, there was again no difference for threatening stimuli
12
13 (g = .08), but an increase in gaze maintenance for depressed individuals for dysphoric stimuli
14
15 (g = .46) and a decrease in positive stimuli (g = -.80) compared to healthy participants.[16]
16
17
18

19
20 Although much of the research in this area includes the use of one patient group in
21
22 comparison to controls, some studies have looked at performance on eye-tracking tasks in
23
24 relation to differential features of depression. For example, non-melancholic depressed patients
25
26 have been found to perform more similarly to control participants than melancholic depressed
27
28 patients for most saccade tasks.[17] Sears and colleagues[18] found that while currently
29
30 dysphoric participants exhibited initial attention orientation biases for both depression-related
31
32 and positive images, previously depressed participants only exhibited a bias for depression-
33
34 related images. This pattern of attention to happy faces was also identified by Isaac and
35
36 colleagues[19], where currently depressed individuals looked at happy faces less than healthy
37
38 controls, but there was no difference between individuals with remitted depression and healthy
39
40 controls in looking time. Severity of depressive scores has also correlated with more abnormal
41
42 performance on their free-viewing task[20]. Different symptom groupings of depression, patient
43
44 history, and severity of depression have all been found to impact eye-tracking measures, and thus
45
46 need to be considered when synthesizing results.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

OBJECTIVES:

The proposed systematic review and meta-analysis will discuss and quantify results from eye-tracking literature with a focus on adults with MDD in comparison to healthy controls, as well as other clinically rated depressive disorders (i.e., persistent depressive disorder/dysthymia, dysphoria, bipolar disorder in depressive phase, disruptive mood dysregulation disorder, premenstrual dysphoric disorder, seasonal affective disorder, minor depression, subthreshold depression). Although excluded in prior literature, inclusion of conditions such as subthreshold depression in research is warranted due to the clinical similarity to MDD.[21] We will include data from saccade, smooth pursuit, fixation, free-viewing, attentional disengagement, and visual search tasks. Additionally, we will cover tasks not previously examined by other reviews (e.g., attentional blink task). Eye-tracking outcomes include, but are not limited to, saccades (number, rate, types), saccadic amplitude and velocity, reaction time, error rate and accuracy (qualitative or quantitative), eye position, fixation count and fixation duration, blinks, and pupil dilation/constriction. As the last systematic review on many of these eye movement tasks was published in 2015, an update on adult eye-tracking in depression is necessary given the growth in literature over the past eight years (see Figure 1). To the authors' knowledge, this will also be the first meta-analysis to include saccade, smooth pursuit, and fixation tasks, as well as blink and pupil measures, which is important as these tasks implicate different neural networks. As a result, this paper may aid in identifying consistent eye movement differences in depression, which may advance the research of biomarker discovery.

METHOD

This protocol covers all items outlined under the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P).[22]

ELIGIBILITY CRITERIA:

Types of studies: Experimental studies performed in a controlled laboratory environment will be included. Any experimental sessions, including longitudinal work, that include eye-tracking measures and eye movement outcomes will be included. Case reports and case series will be excluded.

Types of participants: We will review studies involving study participants with a mean age between 18–60 years. Participants must have a confirmed diagnosis via a standardized diagnostic instrument or clinical judgement (not reliant on self-report measures). Individuals with a current or remitted, primary diagnosis of major depressive disorder, persistent depressive disorder/dysthymia, dysphoria, disruptive mood dysregulation disorder, seasonal affective disorder, minor/subclinical/subthreshold depression, according to established criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM; any version) or of the International Classification of Diseases (ICD; any version). Studies involving individuals with diagnosed bipolar disorder in depressive phase will be included, and studies involving mixed samples of bipolar phases will be included if depressive phase data can be isolated. Studies will not be included if they utilize experimental mood induction procedures in otherwise healthy participants.

Type of control: Studies must also have a control participant group with a mean age between 18-60 years. Though screened controls (no history of mental disorders or psychiatric medication

usage) would be preferred, we will also include studies that do not screen their controls and take this into consideration upon analysis and discussion of results.

Types of interventions: The tasks/measures reviewed by Carvalho et al.[15] will be included: pro-saccades, anti-saccades, predictive saccades, memory-guided saccades, smooth pursuit eye movements, fixation tasks, and free-viewing/attentional disengagement/search tasks, as well as the attentional blink task (see Table 1 for definitions). Additional tasks that are found not to fit in these categories will be included if sufficient data exist. Tasks must have performance (e.g., reaction time, error rate) saccade, pupil, or blink data to be included in analyses.

Task	Definition
Pro-Saccade, Reflexive Saccades, Visually Guided Saccades, Refixation Saccades	Requires participants to look towards a visible stimulus
Anti-Saccade	Requires participants to look away from a visible stimulus
Memory-Guided Saccade	Requires participants to look to a location where a target was previously presented
Predictive Saccade, Oddball Task, Self-Paced Saccade	Requires participants to look to anticipated target location after receiving some warning or cue
Fixation, No Saccade	Requires participants to maintain gaze on a target in the centre of the screen
Free-Viewing	Allows participant to look freely at images or videos that appear
Attentional Disengagement	Requires participants to fixate on a stimulus and then look away when prompted
Visual Search	Requires participant to search for stimuli in a scene, or to compare multiple scenes
Smooth Pursuit	Requires participants to track a moving target
Attentional Blink	Requires participants to report two targets that appear one after another

Table 1. Definition of various eye-movement tasks. [11, 15, 23-24]

Type of outcomes: eye movement outcomes will include, but are not limited to,

Performance metrics: accuracy (qualitative or quantitative), correction factors, error rates, reaction time, response search score

Saccade/fixation metrics: saccade type (back-up, catch-up, corrective, intrusive micro, macro), saccade amplitude, saccade count/rate, saccadic duration, saccadic peak velocity*, saccade position error, intersaccadic interval, direction of initial eye movement, eye scanning length (mean, total), pursuit (gain, latency), first/initial fixation (location, duration, latency), fixation bias, fixation duration, fixation frequencies, fixation number, percentage of time fixating, scan path length, maintenance of gaze, mean gaze duration, final eye position, root mean square, root mean square error, square wave jerk, time-weight average gain, target waveform

Pupil metrics: baseline pupil size, pupil constriction, pupil dilation

Blink metrics: blink duration, blink rate, inter blink interval

*Because of the saccade main sequence relationship, we will scrutinize any velocity comparisons that are not explicitly amplitude matched.

See Table 2 for an overview of patient, intervention, comparison, outcome, and study design (PICO) criteria for inclusion.

PICOs Criteria	Determinants
Patient	Individuals with MDD, persistent depressive disorder/dysthymia, dysphoria, disruptive mood dysregulation disorder, seasonal affective disorder, minor/subclinical/subthreshold depression, or bipolar disorder in depressive phase. Mean age of study sample must be between 18-60 years.
Intervention	Any eye movement tasks (saccade tasks, smooth pursuit tasks, fixation tasks, free-viewing tasks, attentional disengagement tasks, visual search tasks, attentional blink tasks)
Comparison	Healthy individuals, mean of study sample between 18-60 years.
Outcome	Task performance and any eye movement outcome (performance, saccade/fixation, pupil, and blink metrics; see above)
Study design	Experimental non-randomized studies

Table 2. PICO criteria and determinants.

INFORMATION SOURCES:

Journal articles in English, French, German, Dutch, and Portuguese published online up until March 2023 will be reviewed. Included studies will not be limited by geographic location. The electronic databases searched will include PubMed, PsycInfo, EMBASE and Google Scholar. Reference lists of highly relevant articles will also be examined. If full text of papers cannot be accessed, attempts to contact authors will be made. Conference papers, posters, abstracts, and student theses/dissertations will not be included.

SEARCH STRATEGY:

The following is the utilized search strategy for PubMed. All searches will be completed for Title/Abstract and filtered for journal articles and full text availability. The same search strategy will be repeated across databases with minor changes to adjust for database search tools.

Search terms:

1. depress OR mood AND eye tracking OR saccad* OR pupil OR blink OR smooth pursuit
2. dysthymi* AND eye tracking OR saccad* OR pupil OR blink OR smooth pursuit
3. dysphori* AND eye tracking OR saccad* OR pupil OR blink OR smooth pursuit
4. seasonal affective disorder AND eye tracking OR saccad* OR pupil OR blink OR smooth pursuit
5. bipolar AND eye tracking OR saccad* OR pupil OR blink OR smooth pursuit

Search strategies for all databases were determined via consensus among the authors.

STUDY RECORDS:

Data management: Excel spreadsheets will be used to manage records at the level of abstract screening and full text review. BKN will perform the initial search and copy relevant information (authors, publication year, title, link to access) from all search hits and will send the completed spreadsheet to AB.

Selection process: BKN and AB will extract abstracts, screen abstracts for eligibility, and conduct the full-text review independently. Kappa will be used to quantify the level of inter-rater

1
2
3 agreement. DPM and LB will oversee the selection of articles. DPM will provide input on the
4
5 eye-tracking (e.g., evaluation of methodology), and LB will provide input on the clinical aspects
6
7 of the studies. In the event of discrepancies at abstract or full text review, DPM will make the
8
9 decision for discrepancies involving eye-tracking methodology, and LB for discrepancies
10
11 involving participants and all other issues.
12
13

14
15 **Data collection process:** Once included studies have been determined, RevMan will be utilized
16
17 for data extraction and analysis. Data will be extracted by two independent reviewers (BKN and
18
19 AB) in duplicate. Data tables will be independently piloted with 10 papers to ensure all necessary
20
21 information is being extracted.
22
23

24 **Data items:** The following data items will be extracted for saccade and smooth pursuit tasks:
25

26 N (by diagnosis)
27 Mean age and SD
28 Sex/gender
29 Ethnicity
30 Comorbidities
31 Diagnostic method
32 Interventions/treatment
33 Eye movement tasks
34 Eye movement outcomes
35 Results
36
37
38

39 The same data items will be extracted for free-viewing, attentional disengagement, and visual
40
41 search tasks, with the addition of stimuli (type and emotional valence).
42
43

44 **OUTCOMES AND PRIOTIZATION:**

45
46 For a list of eye movement outcomes, see Eligibility Criteria (above). The following outcomes
47
48 will be prioritized due to their frequency in the literature: task accuracy, error rate, fixation
49
50 duration/maintenance of gaze, and reaction time. Additionally, we will prioritize pupil and blink
51
52 outcomes as those have emerged as interesting metrics in our laboratory.
53
54
55
56
57
58
59
60

RISK OF BIAS IN INDIVIDUAL STUDIES:

We will use the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies to assess the risk of bias for each study. Bias will be assessed by two independent researchers (BKN and AB) and discrepancies will be addressed by LB and DPM. This information will not be used to exclude studies but will be reported and narratively discussed.

DATA SYNTHESIS:

The PRISMA flowchart will be presented to explain how and the number of articles that were retrieved/selected. Results from included individual studies will be categorized by eye movement task and expressed both narratively and in data tables. Means, standard deviation, effect sizes, and statistical significance will be reported. It is anticipated that effect sizes will be expressed as Cohen's D. A meta-analysis will be performed if data from three or more studies exist for the same eye movement task. Pending the final study sample, we will also analyze data based on subgroups if three or more studies are available. The proposed subgroups include differential diagnoses (e.g., major depressive disorder versus dysthymia), severity of depressive episode (mild, moderate, severe), and current versus remitted depression. It is anticipated that JASP will be used to do the meta-analyses, though other software will be considered at the time of analyses. To assess whether the results are homogenous, the Q statistic will be calculated.[25] If quantitative synthesis is not appropriate for a subset of data, results will be described narratively.

META-BIASES:

We will investigate in greater detail multiple publications coming out from the same research group and we will assess sample size and sample demographics to check for duplication. In case of overlapping samples/results, the first published reference will be included in the analyses,

1
2
3 unless methodology is not sufficiently detailed to be included. Publication bias will be assessed
4 using a funnel plot method.[26]
5
6

7 **CONFIDENCE IN CUMULATIVE EVIDENCE:**

8
9
10 BKN and AB will independently assess the strength and quality of evidence using Grading of
11 Recommendations, Assessment, Development and Evaluation (GRADE) approach criteria, a tool
12 for meta-analyses that assesses study limitations, inconsistency of results, indirectness of
13 evidence, imprecision, and reporting bias.[27] Strength of evidence will be rated as very low,
14 low, moderate, or high. In the event of discrepancies on GRADE rating, LB and DPM will make
15 the final decision. A quality assessment table will be presented to display which studies were
16 included and which were excluded.
17
18
19
20
21
22
23
24
25

26 **ETHICS AND DISSEMINATION:**

27
28 Ethics approval is not required due to the nature of this work. Results will be analyzed and
29 disseminated according to PRISMA guidelines for systematic review and meta-analyses. We aim
30 to write a scientific publication about the findings. We may also present findings in the form of a
31 poster or oral presentation at one or more scientific conferences.
32
33
34
35
36
37

38 **PATIENT AND PUBLIC INVOLVEMENT:**

39
40 Due to the nature of this study, there will be no patient or public involvement.
41
42
43
44

45 **DISCUSSION**

46
47 There is a growing need to identify reliable biomarkers of mental disorders, specifically
48 as they relate to depressive disorders, to improve early diagnosis and treatment.[28] Research
49 into potential eye movement differences using eye-tracking has grown steadily in recent years, as
50 this method offers the ability to use a variety of different task paradigms and is relatively cost-
51
52
53
54
55
56
57
58
59
60

1
2
3 effective. Given the surge in eye-tracking research in depression, it is paramount to summarize
4 these findings to effectively identify potential behavioural biomarkers.
5
6

7
8 This meta-analysis aims to update the knowledge that has been reported previously by
9
10 past meta-analyses on attentional tasks in depression,[14, 16] provide the first meta-analyses of
11
12 saccade, fixation, and smooth pursuit tasks in depression, as well as to extend the body of
13
14 knowledge by including task paradigms and outcomes not previously covered (e.g., attentional
15
16 blinks). In doing so, we hope to provide a comprehensive overview of current study findings
17
18 which may help inform future clinical practice in the diagnosis and treatment of depression (and
19
20 other related disorders). However, while this meta-analysis will attempt to extend the body of
21
22 knowledge by considering studies using tasks not previously covered by other reviews (e.g.,
23
24 attentional blink task) and those including various depressive disorder populations (i.e., not
25
26 simply individuals diagnosed with MDD), this may be limited by the number of published
27
28 studies and their quality.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 a. Contributorship statement: BKN, DPM, and LB designed the planned systematic review and
4 meta-analysis. BKN drafted the manuscript. AB contributed additional text and edits. DPM and
5 LB reviewed the manuscript and oversaw the work. SKK and GHV provided additional input.
6 All authors approved the final version of the manuscript.
7

8
9 b. Competing interests: The authors have no competing interests to declare.
10

11 c. Funding: The authors received no sources of financial or other support for the protocol or the
12 planned review.
13

14 d. Data sharing statement: Data sharing not applicable as no datasets were generated and/or
15 analysed for this protocol.
16
17
18
19
20
21
22
23

24 Figure 1. Number of results on PubMed for the search query (eye-tracking[Title/Abstract]) AND
25 (depression[Title/Abstract]).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References (APA)

1. World Health Organization, 2017. Depression and Other Common Mental Disorders: Global Health Estimates. <https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf>
2. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). <https://doi.org/10.1176/appi.books.9780890425596>
3. World Health Organization. (2019). *International statistical classification of diseases and related health problems* (11th ed.). <https://icd.who.int/>
4. Kessler R. C. (2012). The costs of depression. *The Psychiatric clinics of North America*, 35(1), 1–14. <https://doi.org/10.1016/j.psc.2011.11.005>
5. Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018). Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. *JAMA psychiatry*, 75(4), 336–346. <https://doi.org/10.1001/jamapsychiatry.2017.4602>
6. Wilson, S., Hicks, B. M., Foster, K. T., McGue, M., & Iacono, W. G. (2015). Age of onset and course of major depressive disorder: associations with psychosocial functioning outcomes in adulthood. *Psychological medicine*, 45(3), 505–514. <https://doi.org/10.1017/S0033291714001640>
7. Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., Jr, & Kasper, S. (2019). Prognosis and improved outcomes in major depression: a review. *Translational psychiatry*, 9(1), 127. <https://doi.org/10.1038/s41398-019-0460-3>
8. Habibi, M., Oertel, W. H., White, B. J., Brien, D. C., Coe, B. C., Riek, H. C., Perkins, J., Yep, R., Itti, L., Timmermann, L., Best, C., Sittig, E., Janzen, A., & Munoz, D. P. (2022). Eye tracking identifies biomarkers in α -synucleinopathies versus progressive supranuclear palsy. *Journal of neurology*, 269(9), 4920–4938. <https://doi.org/10.1007/s00415-022-11136-5>
9. Coe, B. C., & Munoz, D. P. (2017). Mechanisms of saccade suppression revealed in the anti-saccade task. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences*, 372(1718), 20160192. <https://doi.org/10.1098/rstb.2016.0192>
10. Wang, C. A., & Munoz, D. P. (2015). A circuit for pupil orienting responses: implications for cognitive modulation of pupil size. *Current opinion in neurobiology*, 33, 134–140. <https://doi.org/10.1016/j.conb.2015.03.018>
11. Leigh, R.J, & Zee D.S. (Eds.). (2015). *The Neurology of Eye Movements: Fifth Edition*. Oxford <https://doi.org/10.1093/med/9780199969289.001.0001>


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
12. McDowell, J. E., Dyckman, K. A., Austin, B. P., & Clementz, B. A. (2008). Neurophysiology and neuroanatomy of reflexive and volitional saccades: evidence from studies of humans. *Brain and cognition*, 68(3), 255–270. <https://doi.org/10.1016/j.bandc.2008.08.016>
13. Yep, R., Smorenburg, M. L., Riek, H. C., Calancie, O. G., Kirkpatrick, R. H., Perkins, J. E., Huang, J., Coe, B. C., Brien, D. C., & Munoz, D. P. (2022). Interleaved Pro/Anti-saccade Behavior Across the Lifespan. *Frontiers in aging neuroscience*, 14, 842549. <https://doi.org/10.3389/fnagi.2022.842549>
14. Suslow, T., Hußlack, A., Kersting, A., & Bodenschatz, C. M. (2020). Attentional biases to emotional information in clinical depression: A systematic and meta-analytic review of eye tracking findings. *Journal of affective disorders*, 274, 632–642. <https://doi.org/10.1016/j.jad.2020.05.140>
15. Carvalho, N., Laurent, E., Noiret, N., Chopard, G., Haffen, E., Bennabi, D., & Vandael, P. (2015). Eye Movement in Unipolar and Bipolar Depression: A Systematic Review of the Literature. *Frontiers in psychology*, 6, 1809. <https://doi.org/10.3389/fpsyg.2015.01809>
16. Armstrong, T., & Olatunji, B. O. (2012). Eye tracking of attention in the affective disorders: a meta-analytic review and synthesis. *Clinical psychology review*, 32(8), 704–723. <https://doi.org/10.1016/j.cpr.2012.09.004>
17. Winograd-Gurvich, C., Georgiou-Karistianis, N., Fitzgerald, P. B., Millist, L., & White, O. B. (2006). Ocular motor differences between melancholic and non-melancholic depression. *Journal of affective disorders*, 93(1-3), 193–203. <https://doi.org/10.1016/j.jad.2006.03.018>
18. Sears, C.R., Newman, K. R., Ference, J. D., & Thomas, C. L. (2011). Attention to Emotional Images in Previously Depressed Individuals: An Eye-Tracking Study. *Cognitive Therapy and Research*, 35, 517–528. <https://doi.org/10.1007/s10608-011-9396-5>
19. Isaac, L., Vrijssen, J. N., Rinck, M., Speckens, A., & Becker, E. S. (2014). Shorter gaze duration for happy faces in current but not remitted depression: evidence from eye movements. *Psychiatry research*, 218(1-2), 79–86. <https://doi.org/10.1016/j.psychres.2014.04.002>
20. Li, Y., Xu, Y., Xia, M., Zhang, T., Wang, J., Liu, X., He, Y., & Wang, J. (2016). Eye Movement Indices in the Study of Depressive Disorder. *Shanghai archives of psychiatry*, 28(6), 326–334. <https://doi.org/10.11919/j.issn.1002-0829.216078>
21. Noyes, B. K., Munoz, D. P., Khalid-Khan, S., Brietzke, E., & Booij, L. (2022). Is subthreshold depression in adolescence clinically relevant?. *Journal of affective disorders*, 309, 123–130. <https://doi.org/10.1016/j.jad.2022.04.067>

- 1
2
3 22. Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P.,
4 Stewart, L. A., & PRISMA-P Group (2015). Preferred reporting items for systematic
5 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic*
6 *reviews*, 4(1), 1. <https://doi.org/10.1186/2046-4053-4-1>
7
8
9 23. Sanchez, A., Vazquez, C., Marker, C., LeMoult, J., & Joormann, J. (2013). Attentional
10 disengagement predicts stress recovery in depression: an eye-tracking study. *Journal of*
11 *abnormal psychology*, 122(2), 303–313. <https://doi.org/10.1037/a0031529>
12
13 24. Shapiro, K. L., Raymond, J. E., & Arnell, K. M. (1997). The attentional blink. *Trends in*
14 *cognitive sciences*, 1(8), 291–296. [https://doi.org/10.1016/S1364-6613\(97\)01094-2](https://doi.org/10.1016/S1364-6613(97)01094-2)
15
16 25. Cooper, H. (2017). *Research synthesis and meta-analysis: A step-by-step approach* (Vol. 2,
17 5th ed.). Thousand Oaks, CA: Sage Publications, Inc.
18
19 26. Duval, S., & Tweedie, R. (2000). Trim and fill: A simple funnel-plot-based method of testing
20 and adjusting for publication bias in meta-analysis. *Biometrics*, 56(2), 455–463.
21 <https://doi-org.proxy.queensu.ca/10.1111/j.0006-341x.2000.00455.x>
22
23 27. Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P.,
24 Schünemann, H. J., & GRADE Working Group (2008). GRADE: an emerging consensus
25 on rating quality of evidence and strength of recommendations. *BMJ (Clinical research*
26 *ed.)*, 336(7650), 924–926. <https://doi.org/10.1136/bmj.39489.470347.AD>
27
28 28. Kirkpatrick, R. H., Munoz, D. P., Khalid-Khan, S., & Booi, L. (2021). Methodological and
29 clinical challenges associated with biomarkers for psychiatric disease: A scoping
30 review. *Journal of psychiatric research*, 143, 572–579.
31 <https://doi.org/10.1016/j.jpsychires.2020.11.023>
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 License Statement:
4

5 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
6 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive
7 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has
8 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US
9 Federal Government officers or employees acting as part of their official duties; on a worldwide,
10 perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and
11 where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the
12 Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in
13 our [licence](#).
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 The Submitting Author accepts and understands that any supply made under these terms is made
29 by BMJ to the Submitting Author unless you are acting as an employee on behalf of your
30 employer or a postgraduate student of an affiliated institution which is paying any applicable
31 article publishing charge (“APC”) for Open Access articles. Where the Submitting Author
32 wishes to make the Work available on an Open Access basis (and intends to pay the relevant
33 APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence
34 – details of these licences and which [Creative Commons](#) licence will apply to this Work are set
35 out in our licence referred to above.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Number of results on PubMed for the search query (eye-tracking[Title/Abstract]) AND (depression[Title/Abstract]).

163x88mm (300 x 300 DPI)

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page #
ADMINISTRATIVE INFORMATION			
Title:			i
Identification	1a	Identify the report as a protocol of a systematic review	
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	NA
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	i
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	i
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
Support:			
Sources	5a	Indicate sources of financial or other support for the review	NA
Sponsor	5b	Provide name for the review funder and/or sponsor	NA
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	NA
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	1
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	9
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	9

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	9
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	9
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	10
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	10
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	10
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	11
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	11
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	11
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	11
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	11
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	12

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.